279 related articles for article (PubMed ID: 30902072)
1. LUADpp: an effective prediction model on prognosis of lung adenocarcinomas based on somatic mutational features.
Yu J; Hu Y; Xu Y; Wang J; Kuang J; Zhang W; Shao J; Guo D; Wang Y
BMC Cancer; 2019 Mar; 19(1):263. PubMed ID: 30902072
[TBL] [Abstract][Full Text] [Related]
2. Identification and Validation of a Proliferation-Associated Score Model Predicting Survival in Lung Adenocarcinomas.
Bian Y; Sui Q; Bi G; Zheng Y; Zhao M; Yao G; Xue L; Zhang Y; Fan H
Dis Markers; 2021; 2021():3219594. PubMed ID: 34721732
[TBL] [Abstract][Full Text] [Related]
3. Survival prediction for patients with lung adenocarcinoma: A prognostic risk model based on gene mutations.
Geng H; Li S; Guo Y; Yan F; Han Y; Xu M; Cui Y
Cancer Biomark; 2020; 27(4):525-532. PubMed ID: 32083571
[TBL] [Abstract][Full Text] [Related]
4. A large cohort study identifying a novel prognosis prediction model for lung adenocarcinoma through machine learning strategies.
Li Y; Ge D; Gu J; Xu F; Zhu Q; Lu C
BMC Cancer; 2019 Sep; 19(1):886. PubMed ID: 31488089
[TBL] [Abstract][Full Text] [Related]
5. Analysis of genomic and transcriptomic variations as prognostic signature for lung adenocarcinoma.
Zengin T; Önal-Süzek T
BMC Bioinformatics; 2020 Sep; 21(Suppl 14):368. PubMed ID: 32998690
[TBL] [Abstract][Full Text] [Related]
6. EMT network-based feature selection improves prognosis prediction in lung adenocarcinoma.
Shao B; Bjaanæs MM; Helland Å; Schütte C; Conrad T
PLoS One; 2019; 14(1):e0204186. PubMed ID: 30703089
[TBL] [Abstract][Full Text] [Related]
7. Elevated mRNA Levels of AURKA, CDC20 and TPX2 are associated with poor prognosis of smoking related lung adenocarcinoma using bioinformatics analysis.
Zhang MY; Liu XX; Li H; Li R; Liu X; Qu YQ
Int J Med Sci; 2018; 15(14):1676-1685. PubMed ID: 30588191
[No Abstract] [Full Text] [Related]
8. Association of specific gene mutations derived from machine learning with survival in lung adenocarcinoma.
Cho HJ; Lee S; Ji YG; Lee DH
PLoS One; 2018; 13(11):e0207204. PubMed ID: 30419062
[TBL] [Abstract][Full Text] [Related]
9. The genomic alterations of lung adenocarcinoma and lung squamous cell carcinoma can explain the differences of their overall survival rates.
Meng F; Zhang L; Ren Y; Ma Q
J Cell Physiol; 2019 Jul; 234(7):10918-10925. PubMed ID: 30549039
[TBL] [Abstract][Full Text] [Related]
10. Identifying the miRNA signature associated with survival time in patients with lung adenocarcinoma using miRNA expression profiles.
Yerukala Sathipati S; Ho SY
Sci Rep; 2017 Aug; 7(1):7507. PubMed ID: 28790336
[TBL] [Abstract][Full Text] [Related]
11. Molecular subtypes based on DNA promoter methylation predict prognosis in lung adenocarcinoma patients.
Shi S; Xu M; Xi Y
Aging (Albany NY); 2020 Nov; 12(23):23917-23930. PubMed ID: 33237038
[TBL] [Abstract][Full Text] [Related]
12. Comparative analysis of machine learning approaches to classify tumor mutation burden in lung adenocarcinoma using histopathology images.
Sadhwani A; Chang HW; Behrooz A; Brown T; Auvigne-Flament I; Patel H; Findlater R; Velez V; Tan F; Tekiela K; Wulczyn E; Yi ES; Mermel CH; Hanks D; Chen PC; Kulig K; Batenchuk C; Steiner DF; Cimermancic P
Sci Rep; 2021 Aug; 11(1):16605. PubMed ID: 34400666
[TBL] [Abstract][Full Text] [Related]
13. Identification and validation of hypoxia-derived gene signatures to predict clinical outcomes and therapeutic responses in stage I lung adenocarcinoma patients.
Shi R; Bao X; Unger K; Sun J; Lu S; Manapov F; Wang X; Belka C; Li M
Theranostics; 2021; 11(10):5061-5076. PubMed ID: 33754044
[No Abstract] [Full Text] [Related]
14. A novel strategy of integrated microarray analysis identifies CENPA, CDK1 and CDC20 as a cluster of diagnostic biomarkers in lung adenocarcinoma.
Liu WT; Wang Y; Zhang J; Ye F; Huang XH; Li B; He QY
Cancer Lett; 2018 Jul; 425():43-53. PubMed ID: 29608985
[TBL] [Abstract][Full Text] [Related]
15. NCC-AUC: an AUC optimization method to identify multi-biomarker panel for cancer prognosis from genomic and clinical data.
Zou M; Liu Z; Zhang XS; Wang Y
Bioinformatics; 2015 Oct; 31(20):3330-8. PubMed ID: 26092859
[TBL] [Abstract][Full Text] [Related]
16. Development of somatic mutation signatures for risk stratification and prognosis in lung and colorectal adenocarcinomas.
Menor M; Zhu Y; Wang Y; Zhang J; Jiang B; Deng Y
BMC Med Genomics; 2019 Jan; 12(Suppl 1):24. PubMed ID: 30704450
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathologic characteristics and prognostic significance of EGFR and p53 mutations in surgically resected lung adenocarcinomas ≤2 cm in maximal dimension.
Lin MW; Wu CT; Shih JY; Chang YL; Yang PC
J Surg Oncol; 2014 Aug; 110(2):99-106. PubMed ID: 24788590
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive characterization of functional eRNAs in lung adenocarcinoma reveals novel regulators and a prognosis-related molecular subtype.
Qin N; Ma Z; Wang C; Zhang E; Li Y; Huang M; Chen C; Zhang C; Fan J; Gu Y; Xu X; Yang L; Wei X; Yin R; Jiang Y; Dai J; Jin G; Xu L; Hu Z; Shen H; Ma H
Theranostics; 2020; 10(24):11264-11277. PubMed ID: 33042282
[No Abstract] [Full Text] [Related]
19. Exploring the survival prognosis of lung adenocarcinoma based on the cancer genome atlas database using artificial neural network.
Jiang N; Xu X
Medicine (Baltimore); 2019 May; 98(20):e15642. PubMed ID: 31096483
[TBL] [Abstract][Full Text] [Related]
20. Genome-scale analysis to identify prognostic markers and predict the survival of lung adenocarcinoma.
Li YY; Yang C; Zhou P; Zhang S; Yao Y; Li D
J Cell Biochem; 2018 Nov; 119(11):8909-8921. PubMed ID: 30105759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
